

Enzon Incorporated

[View the current Enzon Incorporated Page on BioPortfolio.com](http://www.bioportfolio.com/bi corporate/3851-Enzon+Incorporated.html)

(<http://www.bioportfolio.com/bi corporate/3851-Enzon+Incorporated.html>)

Contact Details:

20 Kingsbridge Road

Piscataway

NJ

08854

United States of America

Tel: 732 980 4500

Fax: 732 980 5911

Email:

Enzon Incorporated is a biopharmaceutical company that develops, manufactures and markets enhanced therapeutics for life-threatening diseases through the application of its two proprietary technologies: (i) polyethylene glycol ("PEG") Modification or the PEG Process and (ii) single-chain antigen-binding ("SCA(R)") proteins. Enzon is focusing its internal research activities on applying its proprietary technologies to compounds of known therapeutic efficacy in order to enhance the performance of these compounds. Enzon is commercializing its proprietary technologies by developing products internally and in cooperation with strategic partners. To date, Enzon and its partners have successfully commercialized two products, ONCASPAR(R) and ADAGEN(R).

Recent Publications by Enzon Incorporated:



- [Marked therapeutic efficacy of a novel polyethylene glycol-SN38 conjugate, EZN-2208, in xenograft models of B-cell non-Hodgkin's lymphoma.](#)
*Examination of the clinical utility of SN38...*2nd October, 2009
Enzon Pharmaceuticals, Inc., 20 Kingsbridge Road, Piscataway, NJ 08854,- Haematologica. 2009 Oct;94(10):1456-9. ([DOI Direct Link](#))
- [A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth.](#)
*Hypoxia-inducible factor-1 (HIF-1) is a transcription factor that plays a...*23rd December, 2008
Enzon Pharmaceuticals Inc., 20 Kingsbridge Road, Piscataway, NJ 08854,- Mol Cancer Ther. 2008 Nov;7(11):3598-608. Epub 2008 Oct 30. ([DOI Direct Link](#))
- [I \$\kappa\$ B \$\alpha\$ kinase inhibitor IKI-1 conferred tumor necrosis factor alpha sensitivity to pancreatic cancer cells and a xenograft tumor model.](#)
*Tumor necrosis factor alpha (TNF α) has been used to treat patients...*17th December, 2008
Department of Oncology, Wyeth Research, Pearl River, New York, USA.- Cancer Res. 2008 Nov

- 15;68(22):9519-24. ([DOI Direct Link](#))
- [Novel prodrugs of SN38 using multiarm poly\(ethylene glycol\) linkers.](#)
*CPT-11, also known as irinotecan, is a prodrug that is approved for the...*29th July, 2008
 Enzon Pharmaceuticals, Inc., 20 Kingsbridge Road, Piscataway, New Jersey- Bioconjug Chem. 2008
 Apr;19(4):849-59. Epub 2008 Mar 28. ([DOI Direct Link](#))
 - [Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model.](#)
*PURPOSE: Clinical development of SN38, the active metabolite of...*21st May, 2008
 Enzon Pharmaceuticals, Inc., Piscataway, New Jersey 08854, USA.- Clin Cancer Res. 2008 Mar
 15;14(6):1888-96. ([DOI Direct Link](#))
 - [Releasable PEGylation of proteins with customized linkers.](#)
*Releasable PEGylation employs customized linkers that reversibly tether a...*6th May, 2008
 Enzon Pharmaceuticals, Inc., 20 Kingsbridge Road, Piscataway, New Jersey- Adv Drug Deliv Rev.
 2008 Jan 3;60(1):29-49. Epub 2007 Aug 16. ([DOI Direct Link](#))
 - [Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice.](#)
*Recombinant immunotoxins exhibit targeting and cytotoxic functions needed...*30th August, 2007
 Enzon Pharmaceuticals, Incorporated, 20 Kingsbridge Road, Piscataway, New- Bioconjug Chem. 2007
 May-Jun;18(3):773-84. Epub 2007 Mar 9. ([DOI Direct Link](#))
 - [Antibody engineering and modification technologies.](#)
*Antibody engineering has become a well-developed discipline, encompassing...*27th July, 2007
 Enzon Pharmaceuticals, Piscataway, NJ 08854-3969, USA.- Biomol Eng. 2007 Jun;24(2):201-15. Epub
 2007 Mar 31. ([DOI Direct Link](#))
 - [Delivery of G3139 using releasable PEG-linkers: impact on pharmacokinetic profile and anti-tumor efficacy.](#)
*In order to overcome the problems of enzymatic degradation and short...*11th July, 2007
 Enzon Pharmaceuticals, 20 Kingsbridge Road, Piscataway, NJ 08820, United- J Control Release. 2007
 Jun 4;119(2):143-52. Epub 2006 Dec 29. ([DOI Direct Link](#))
 - [Comparative immunotoxicity evaluation of amphotericin B and ABELCET, an amphotericin B lipid complex \(ABLC\).](#)
*ABELCET, an amphotericin B lipid complex formulation (ABLC) and an...*8th February, 2007
 Enzon Pharmaceuticals, Inc., Piscataway, New Jersey 08854, USA.- Int J Toxicol. 2006
 Nov-Dec;25(6):487-92. ([DOI Direct Link](#))
 - [Antitumor activity of poly\(ethylene glycol\)-camptothecin conjugate: the inhibition of tumor growth in vivo.](#)
*Antitumor effect of poly(ethylene glycol)-camptothecin conjugate (PEG-CPT)...*20th January, 2007
 Enzon Pharmaceuticals, Inc., Piscataway, NJ 08854, USA.- J Control Release. 2005 Dec
 10;110(1):90-102. Epub 2005 Nov 4. ([DOI Direct Link](#))
 - [Engineering an arginine catabolizing bioconjugate: Biochemical and pharmacological characterization of PEGylated derivatives of arginine deiminase from Mycoplasma arthritidis.](#)
*Arginine is an important metabolite in the normal function of several...*16th January, 2007
 Enzon Pharmaceuticals, 20 Kingsbridge Road, Piscataway, New Jersey- Bioconjug Chem. 2006
 Nov-Dec;17(6):1447-59. ([DOI Direct Link](#))
 - [Safety evaluation of ABELCET, an amphotericin B lipid complex \(ABLC\): toxicity studies in rats.](#)
*ABELCET (ABLC) is a widely used amphotericin B lipid complex formulation...*19th August, 2006
 Enzon Pharmaceuticals, Inc., Piscataway, New Jersey, USA.- Int J Toxicol. 2006 Jul-Aug;25(4):285-94.
 ([DOI Direct Link](#))
 - [Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation.](#)
*Recombinant interferon-beta-1b (IFN-beta-1b) is used clinically in the...*25th July, 2006
 Enzon Pharmaceuticals, 20 Kingsbridge Road, Piscataway, New Jersey- Bioconjug Chem. 2006
 May-Jun;17(3):618-30. ([DOI Direct Link](#))
 - [Linear and branched bicine linkers for releasable PEGylation of macromolecules: controlled release in vivo and in vitro from mono- and multi-PEGylated proteins.](#)

Press Releases on Enzon Incorporated:

H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics	20th November, 2009	Quest Diagnostics Incorporated	<i>-- Rates of positive test results for the pandemic have declined in recent weeks in most regions, with the exception of the Northeast, where rates have more than doubled during</i>
New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce, According to Quest Diagnostics Drug Testing Index(TM)	20th November, 2009	Quest Diagnostics Incorporated	<i>MADISON, N.J., Nov. 20 /PRNewswire-FirstCall/ -- New data released today by Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of employment-related drug testing services,</i>
Spherix Announces the Closing of \$6.3 Million Registered Direct Offering	19th November, 2009	Spherix Incorporated	<i>BETHESDA, Md., Nov. 19 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting</i>
Spherix Announces Results of Annual Shareholders Meeting	19th November, 2009	Spherix Incorporated	<i>-- Robert J. Vander Zanden, Ph.D., former Vice President, R&D, Kraft Foods International In addition, Grant Thornton LLP was ratified as the Company's independent accountants</i>
Give Your Pooch the Gift of Wisdom This Holiday	19th November, 2009	Mars Veterinary	<i>ROCKVILLE, Md., Nov. 19 /PRNewswire/ -- There is no greater love than the adoration you receive from man's best friend. This holiday season, return the love by gifting your four legged friend</i>

BioNews Results for Enzon Incorporated



- [Bauposts Seth Klarman Buys Enzon Inc., Viasat Inc., Sells Horizon Lines Inc., News Corp., PDL Biopharma Inc](#)
Guru Focus: Nov 13 2009 4:55AM Matching: enzon
- [Form 8-K ENZON PHARMACEUTICALS For: Nov 09](#)
Street Insider: Nov 12 2009 1:53PM Matching: enzon
- [Enzon to Sell Its Specialty Pharmaceutical Business](#)
TradingMarkets: Nov 11 2009 6:11AM Matching: enzon
- [Enzon Pharma to sell specialty pharma biz to Sigma-Tau Group for US\\$ 300 mn](#)
PharmaBiz: Nov 11 2009 4:21AM Matching: enzon
- [Enzon Announces Agreement to Sell Specialty Pharmaceutical Business](#)
PipelineReview: Nov 11 2009 1:12AM Matching: enzon
- [Enzon sells specialty pharma biz to Sigma Tau for \\$327mn](#)
Bio Spectrum Asia: Nov 11 2009 11:33AM Matching: enzon
- [Enzon sells specialty pharmaceutical biz to Sigma Tau for \\$327mn](#)
Bio Spectrum Asia: Nov 11 2009 11:24AM Matching: enzon
- [Enzon to Sell Its Specialty Pharmaceutical Business to sigma-tau for Approximately \\$327 million](#)
PharmaceuticalProcessing: Nov 11 2009 7:27PM Matching: enzon
- [Zacks Analyst Blog Highlights: Enzon, Merck, OSI Pharmaceuticals, Pfizer and Bank of America Corporation](#)
Yahoo! Canada: Nov 11 2009 10:15PM Matching: enzon
- [Zacks Analyst Blog Highlights: Enzon, Merck, OSI Pharmaceuticals, Pfizer and Bank of America Corporation](#)
PR inside: Nov 11 2009 10:14PM Matching: enzon
- [Zacks Analyst Blog Highlights: Enzon, Merck, OSI Pharmaceuticals, Pfizer and Bank of America Corporation](#)
Business Wire UK: Nov 11 2009 10:12PM Matching: enzon
- [Zacks Analyst Blog Highlights: Enzon, Merck, OSI Pharmaceuticals, Pfizer and Bank of America Corporation](#)
Business Wire: Nov 11 2009 10:07PM Matching: enzon
- [Zacks Analyst Blog Highlights: Enzon, Merck, OSI Pharmaceuticals, Pfizer and Bank of America Corporation](#)
Reuters: Nov 11 2009 11:22PM Matching: enzon
- [Zacks Analyst Blog Highlights: Enzon, Merck, OSI Pharmaceuticals,](#)
Business Wire via MSN Money: Nov 11 2009 10:19PM Matching: enzon
- [Enzon Pharmaceuticals to sell specialty pharmaceutical business to Sigma-Tau Deal In Brief](#)
Quote.com Italy: Nov 11 2009 10:06AM Matching: enzon

Enzon Incorporated Clinical Trials:



- [Efficacy of Pegamotecan \(PEG-Camptothecin\) in Localized or Metastatic Cancer of the Stomach or Gastroesophageal Junction](#)



Enzon Incorporated Patents:

- 6121424- [Multivalent antigen-binding proteins](#)
- 6515110- [Multivalent antigen-binding proteins](#)
- 6566506- [Non-antigenic branched polymer conjugates](#)
- 6608076- [Camptothecin derivatives and polymeric conjugates thereof](#)
- 6624142- [Trimethyl lock based tetrapartate prodrugs](#)
- 6638499- [Terminally-branched polymeric linkers and polymeric conjugates containing the same](#)
- 6649778- [Methods of preparing amino acid taxane derivatives and polymer conjugates containing the same](#)
- 6689762- [Composition and methods for treatment of HIV infection](#)
- 6692942- [Single-chain polypeptides for targeted delivery of nucleic acids](#)
- 6720306- [Tetrapartate prodrugs](#)
- 6743896- [Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof](#)
- 6395266- [Terminally-branched polymeric linkers and polymeric conjugates containing the same](#)
- 6376470- [Polymer conjugates of ara-C and ara-C derivatives](#)
- 6333396- [Method for targeted delivery of nucleic acids](#)
- 6127355- [High molecular weight polymer-based prodrugs](#)
- 6132713- [Arginine deiminase derived from mycoplasma arthritis and polymer conjugates containing the same](#)
- 6153655- [Terminally-branched polymeric linkers and polymeric conjugates containing the same](#)
- 6177087- [Non-antigenic amine derived polymers and polymer conjugates](#)
- 6180095- [Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents](#)
- 6194580- [High yield method for stereoselective acylation of tertiary alcohols](#)
- 6214330- [Coumarin and related aromatic-based polymeric prodrugs](#)
- 6251382- [Biodegradable high molecular weight polymeric linkers and their conjugates](#)
- 6303569- [Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents](#)
- 6323322- [Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof](#)
- 6743908- [Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof](#)
- 6756037- [Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups](#)
- 7332164- [Heterobifunctional polymeric bioconjugates](#)
- 7365127- [Process for the preparation of polymer conjugates](#)
- 7393953- [Polymeric acyl derivatives of indoles](#)
- 7413738- [Releasable polymeric conjugates based on biodegradable linkers](#)
- 7462627- [Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers](#)
- 7462687- [Prodrugs of vancomycin with hydrolysis resistant polymer linkages](#)
- 7569657- [Methods of preparing polymers having terminal amine groups using protected amine salts](#)
- 7584675- [Connector enabling multiple sampling of sealed environment](#)
- 7589190- [Potent LNA oligonucleotides for the inhibition of HIF-1A expression](#)
- 7595304- [Polymeric oligonucleotide prodrugs](#)
- 7301003- [Method of preparing polymers having terminal amine groups](#)
- 7273845- [Polymeric prodrugs of vancomycin](#)
- 7262164- [Polymeric thiol-linked prodrugs employing benzyl elimination systems](#)
- 6764853- [Method for targeted delivery of nucleic acids](#)

- 6777387- [Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same](#)
- 6824766- [Biodegradable high molecular weight polymeric linkers and their conjugates](#)
- 6824782- [Polyalkylene oxide-modified single chain polypeptides](#)
- 6872393- [Polyalkylene oxide-modified single chain polypeptides](#)
- 6936597- [Prodrugs of anticancer agents employing substituted aromatic acids](#)
- 7033583- [Polymeric thiol-linked prodrugs](#)
- 7087229- [Releasable polymeric conjugates based on aliphatic biodegradable linkers](#)
- 7122189- [Releasable polymeric conjugates based on aliphatic biodegradable linkers](#)
- 7150872- [Polyalkylene oxide-modified single chain polypeptides](#)
- 7601798- [Methods of preparing polymers having terminal amine groups using protected amine salts](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road,

